<DOC>
	<DOCNO>NCT00391976</DOCNO>
	<brief_summary>This study assess time recurrence infection Pseudomonas aeruginosa follow treatment initial infection tobramycin nebuliser solution . The safety profile initial tobramycin treatment assess first 3 month study patient follow end study , month 27 .</brief_summary>
	<brief_title>Efficacy Safety 28 56 Day Treatment Pseudomonas Aeruginosa Children With Cystic Fibrosis</brief_title>
	<detailed_description>This multi-center , open-label , two-arm , randomize study . All patient diagnose CF fulfil criterion early infection P. aeruginosa initially receive tobramycin 300 mg twice day 28 day . At end 28-day treatment period , patient meet inclusion criterion none additional exclusion criterion randomize 1:1 ratio either receive additional 28 day treatment tobramycin 300 mg twice day ( 56-day group ) stop study medication ( 28-day group ) . All randomized patient regular study visit positive P. aeruginosa sample obtain . Once P. aeruginosa recur , patient enter follow-up phase minimal information collect 27 month . During follow-up phase , patient treat accord physician ' discretion . Patients start treatment tobramycin randomize ( i.e . due positive antibody test ) follow routine clinic visit . They allow continue 28-day treatment period afterwards treat accord physician ' discretion .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Inclusion criterion : Male female patient ≥ 6 month old Diagnosis cystic fibrosis ( CF ) base upon follow historical criterion perform prior study participation : 1. confirm sweat chloride &gt; 60 mEq/L quantitative pilocarpine iontophoresis ( least 2 test ) , OR 2. genotype two identifiable mutation consistent CF . First early low respiratory tract infection Pseudomonas ( P. ) aeruginosa document either follow : 1. first infection define first P. aeruginosa isolate sputum deep throat cough swab culture , OR 2 . P. aeruginosa sputum deep throat cough swab culture follow least 1 year negative culture ( document least 4 negative culture year positive culture ) antipseudomonal treatment 1year period , OR 3 . P. aeruginosa sputum deep throat cough swab culture follow least 2 year negative culture ( document least 2 negative culture per year positive culture ) antipseudomonal treatment 2year period . Written informed consent patient and/or parent/legal guardian accord local country regulation . Exclusion criterion : History aminoglycoside hypersensitivity adverse reaction inhale aminoglycoside . Signs symptom acute pulmonary disease , eg , pneumonia , pneumothorax . Administration investigational drug within 30 day prior enrollment . Administration loop diuretic within 7 day prior study drug administration . Personal/family history abnormal hearing , typical hearing loss associate age process . Abnormal result audiology test ( define either unilateral puretone audiometry test show threshold elevation &gt; 20 decibel [ dB ] frequency across frequency range 0.258 kHz absence emission evoke otoacoustic emission test ) . Positive urine pregnancy test Day 1 ( Baseline ) female patient reach menarche . Use macrolide antibiotic maintenance therapy 12 day 28 day prior Baseline . Antibody titer ≥ 1000 3 P. aeruginosa exoenzymes : Exotoxin A , alkaline protease , elastase ( status determine Baseline Day 28 ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Cystic fibrosis</keyword>
</DOC>